ADMA Biologics (ADMA) Stock Price, News & Analysis

-0.07 (-1.07%)
(As of 03:46 PM ET)
Today's Range
50-Day Range
52-Week Range
1.11 million shs
Average Volume
2.64 million shs
Market Capitalization
$1.48 billion
P/E Ratio
Dividend Yield
Price Target

ADMA Biologics MarketRank™ Stock Analysis

Analyst Rating
3.25 Rating Score
22.3% Upside
$7.88 Price Target
Short Interest
3.19% of Shares Sold Short
Dividend Strength
News Sentiment
Insider Trading
Selling Shares
$3.93 M Sold Last Quarter
Proj. Earnings Growth
From $0.30 to $0.50 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.10 out of 5 stars

Medical Sector

346th out of 909 stocks

Biological Products, Except Diagnostic Industry

49th out of 156 stocks

ADMA stock logo

About ADMA Biologics Stock (NASDAQ:ADMA)

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Stock Price History

ADMA Stock News Headlines

ADMA Biologics Inc
The A.I. story nobody is telling you (Read ASAP)
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
A Closer Look at 6 Analyst Recommendations For ADMA Biologics
The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
ADMA Apr 2024 5.000 put
Q4 2023 ADMA Biologics Inc Earnings Call
ADMA Biologics, Inc.: ADMA Biologics Announces CFO Transition
Forecasting The Future: 4 Analyst Projections For ADMA Biologics
ADMA Biologics' CFO to step down
ADMA Biologics Announces CFO Transition
See More Headlines
Receive ADMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$258.21 million
Cash Flow
$0.05 per share
Book Value
$0.60 per share


Free Float
Market Cap
$1.49 billion
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

ADMA Stock Analysis - Frequently Asked Questions

Should I buy or sell ADMA Biologics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADMA shares.
View ADMA analyst ratings
or view top-rated stocks.

What is ADMA Biologics' stock price target for 2024?

4 equities research analysts have issued twelve-month price targets for ADMA Biologics' shares. Their ADMA share price targets range from $6.00 to $10.00. On average, they expect the company's share price to reach $7.88 in the next year. This suggests a possible upside of 22.3% from the stock's current price.
View analysts price targets for ADMA
or view top-rated stocks among Wall Street analysts.

How have ADMA shares performed in 2024?

ADMA Biologics' stock was trading at $4.52 on January 1st, 2024. Since then, ADMA shares have increased by 42.5% and is now trading at $6.44.
View the best growth stocks for 2024 here

Are investors shorting ADMA Biologics?

ADMA Biologics saw a drop in short interest in March. As of March 31st, there was short interest totaling 7,290,000 shares, a drop of 8.8% from the March 15th total of 7,990,000 shares. Based on an average daily volume of 2,750,000 shares, the days-to-cover ratio is currently 2.7 days.
View ADMA Biologics' Short Interest

When is ADMA Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ADMA earnings forecast

How were ADMA Biologics' earnings last quarter?

ADMA Biologics, Inc. (NASDAQ:ADMA) issued its earnings results on Wednesday, February, 28th. The biotechnology company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.02. The biotechnology company had revenue of $73.90 million for the quarter, compared to the consensus estimate of $73.50 million. ADMA Biologics had a negative net margin of 10.94% and a positive trailing twelve-month return on equity of 0.49%.

What guidance has ADMA Biologics issued on next quarter's earnings?

ADMA Biologics issued an update on its FY 2025 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $380.0 million-.

What is Adam S. Grossman's approval rating as ADMA Biologics' CEO?

9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

Who are ADMA Biologics' major shareholders?

ADMA Biologics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.47%), Rice Hall James & Associates LLC (0.53%), PFG Investments LLC (0.15%), Raymond James Financial Services Advisors Inc. (0.11%), Allspring Global Investments Holdings LLC (0.11%) and First Hawaiian Bank (0.05%). Insiders that own company stock include Adam S Grossman, Brian Lenz, Bryant Fong, Jerrold B Grossman, Perceptive Advisors Llc, Steve Elms and Young Kwon.
View institutional ownership trends

How do I buy shares of ADMA Biologics?

Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADMA) was last updated on 4/24/2024 by Staff

From Our Partners